Global Allogeneic Cell Therapy Market Report 2023-2035: Celularity, Allogene Therapeutics, and Fate Therapeutics Driving Innovation, Heralding a New Era in Regenerative Medicine

News provided by

Aug 08, 2023, 19:30 ET

DUBLIN, Aug. 8, 2023 /PRNewswire/ -- The "Allogeneic Cell Therapy: Global Market Report 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The global allogeneic cell therapy market is estimated at USD 900 million in 2023, and is projected to grow at a compounded annual growth rate (CAGR) of 14% during the forecast period, 2023 to 2035.

In the realm of regenerative medicine, the spotlight is firmly on allogeneic cell therapies – an innovative approach that promises to reshape how we treat various disorders. This comprehensive overview takes a deep dive into the forces driving this transformative field, ranging from the advantages of allogeneic therapies over autologous counterparts to the dynamic landscape of partnerships, clinical trials, and regional market trends.

Diverging Paths: Allogeneic vs. Autologous Cell Therapies

Allogeneic and autologous cell therapies represent distinct avenues within regenerative medicine. Autologous therapies involve using a patient's own cells, which are processed and reintroduced. While personalized, this process is time-consuming. Allogeneic therapies, on the other hand, utilize donor cells that are readily available, scalable, and cost-effective. They eliminate the need for personalized production, ensuring uniform quality, lower costs, and the flexibility to approach different donors for subsequent treatments.

Pipeline and Clinical Insights: A Global Wave of Innovation

The allogeneic cell therapy market is in the midst of a significant wave of innovation, with a vast array of stakeholders driving the development of therapies for diverse indications. Currently, over 470 allogeneic cell therapies are under evaluation across different developmental stages. These therapies target a range of disorders from infectious diseases to neurological and oncological disorders, signaling the wide-reaching potential of allogeneic approaches.

Recent approvals, such as Gamida Cell's Omisirge for hematologic malignancies, underscore the market's momentum. As industry and non-industry players collaborate and clinical trial results continue to inspire confidence, the allogeneic cell therapy landscape is evolving at an accelerated pace.

Partnerships: The Catalysts of Innovation

Collaboration has become a cornerstone of the allogeneic cell therapy market's growth. Companies are forming strategic partnerships to bolster research, development, and commercialization efforts. These alliances facilitate knowledge sharing, resource utilization, and access to complementary expertise, thereby accelerating the journey toward innovative allogeneic therapies.

For instance, Tessa Therapeutics' collaboration with the US National Cancer Institute demonstrates the potential of collaborative ventures in advancing allogeneic therapies. Over 90 partnerships established since 2019 highlight the enthusiasm within the sector to push the boundaries of innovation collectively.

Investment and Funding: Nurturing Breakthroughs

Investor interest in the allogeneic cell therapy market is evident from the significant funds raised by companies engaged in this space. Over the last four years, approximately USD 8.8 billion has been invested globally. Venture rounds have played a pivotal role in funding, indicating the growing confidence in the market's transformative potential.

This influx of funds not only fuels the development of allogeneic cell therapies but also spurs technological advancements and innovative breakthroughs.

Market Growth Factors: Challenges and Opportunities

Several factors drive the growth of the allogeneic cell therapy market. The ongoing dedication of industry and non-industry players, coupled with the prevalence of chronic and non-malignant disorders, is fostering the development and adoption of allogeneic therapies. Moreover, the challenges associated with producing autologous cell therapies, which are personalized and time-intensive, further underscore the transformative potential of allogeneic therapies.

Clinical Trials: Unveiling Efficacy and Safety

The robust allogeneic cell therapy landscape is supported by a plethora of clinical trials evaluating the effectiveness and safety of these therapies. Over 365 clinical trials are registered, targeting diverse indications such as hematologic malignancies, infectious diseases, neurological disorders, and more. North America dominates this arena, with around 55% of total enrollments.

The promising outcomes of clinical trials, like Allogene's ALLO-715 allogeneic CAR T cell therapy for multiple myeloma, underscore the credibility of allogeneic cell therapies and their potential to revolutionize treatment approaches.

Regional Market Insights: North America's Leadership

With a thriving ecosystem of allogeneic cell therapy developers, North America is poised to capture over 60% of the global market share by 2035. Rising disease prevalence, FDA approvals, and government support for reimbursement are propelling the region's market growth. The government's recognition of allogeneic cell therapies' transformative potential in enhancing patient outcomes is a testament to the industry's impact.

Key Players and Prospects for the Future

Numerous key players are actively pushing the boundaries of allogeneic cell therapies, targeting diverse indications. Players like Celularity, Allogene Therapeutics, and Fate Therapeutics are driving innovation. As these players continue to innovate and gain approvals, the allogeneic cell therapy market is on track for substantial growth, heralding a new era in regenerative medicine.

Allogeneic Cell Therapy Market Research Conclusion

The global allogeneic cell therapy market is in the midst of a remarkable journey, fueled by innovation, collaboration, investment, and promising clinical trial results. Allogeneic therapies hold the potential to revolutionize healthcare delivery through their immediate availability, scalability, and cost-effectiveness. With industry and non-industry players relentlessly pushing boundaries, the allogeneic cell therapy market is primed for robust growth, ushering in a new era of possibilities in regenerative medicine.

Key Topics Covered

1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.2. Allogeneic Cell Therapies: Developer Landscape

5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.2. Allogeneic Cell Therapies: Partnerships and Collaborations

6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments

7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis

8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035

10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Mesoblast
10.3. Triumvira Immunologics

11. APPENDIX I: TABULATED DATA

12. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (378 Total)

920th Hospital of Joint Logistics Support Force
AbbVie
Academisch Medisch Centrum
Acepodia
Adaptimmune Therapeutics
Adicet Bio
Aegle Therapeutics
Affiliated Hospital to Academy of Military Medical Sciences
Affimed
Alaunos Therapeutics
Allogene Therapeutics
AlloVir
Alpha Biopharma
Altaco XXI
Amgen
Angiocrine Bioscience
Anhui Provincial Hospital
Ann & Robert H. Lurie Children's Hospital of Chicago
Anterogen
Antion Biosciences
APICES
Athersys
Artiva Biotherapeutics
Astellas Pharma
Atara Biotherapeutics
Athenex
Athersys
Autolomous
Azidus Brasil
Bayer
Baylor College of Medicine
Baylx
Be The Match BioTherapies
Beijing 302 Hospital
Beijing Doing Biomedical
Beijing GD Initiative Cell Therapy Technology
Beijing Immunochina Medical Science & Technology
JD Biotech
Beijing SH biotechnology
Beth Israel Deaconess Medical Center
BHI Therapeutic Sciences
BioCardia
Bioceltech Therapeutics
BioCentriq
Biomedical Advanced Research and Development Authority (BARDA)
Biorasi
Bioray Laboratories
BioSenic (Previously known as Bone Therapeutics)
Bristol Myers Squibb
California Institute for Regenerative Medicine
Cancer Research UK
Capricor Therapeutics
CardioCell
Caribou Biosciences
Cartesian Therapeutics
Junta de Castilla y Leon
Catalent Pharma Solutions
Catamaran Bio
Cedars-Sinai Medical Center
Celixir
Cell2Cure
Cellavita
Cell and Gene Therapy Catapult
Cellectis
Cellenkos
Cellerant Therapeutics
Cellerix
Celltex Therapeutics
Cellular Biomedicine Group (CBMG)
Celularity
Celyad Oncology
Center for Breakthrough Medicines
Central South University
Centre Hospitalier Universitaire de Limoges
Chabiotech
Chandler Regional Medical Center
Changhai Hospital
Huaxia Intech (Biotech) Biotechnology (Previously known as China Immunotech Biotechnology)
China-Japan Friendship Hospital
Chinese Academy of Medical Sciences
Chinese PLA General Hospital
Cipla
Citospin
Cleveland Clinic
Cliniques universitaires Saint-Luc
CoImmune
Copenhagen University Hospital
Corestem
CRISPR Therapeutics
Cynata Therapeutics
CytoMed Therapeutics
Cytopeutics
Cytora
Cytovia Therapeutics
Daewoong Pharmaceutical
Department of Health and Human Services
Deverra Therapeutics
Direct Biologics
DiscGenics
Dt&SanoMedics
Duke University
EdiGene
Editas Medicine
ElevateBio
ENCell
Enlivex Therapeutics
European Commission
European Union
Ever Supreme Bio Technology
Fate Therapeutics
Ferrer Internacional
FGK Clinical Research
FibroBiologics
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Formula Pharmaceuticals
Fortress Biotech
Fred Hutchinson Cancer Center
Fresno Community Hospital and Medical Center
FUJIFILM Diosynth Biotechnologies
Fundamenta Therapeutics
Gamida Cell
GC Cell
Gemeinsamer Bundesausschuss
Genentech
GentiBio
Genzyme
Ghent University
Global Cord Blood Corporation
Glycostem Therapeutics
Gracell Biotechnologies
Granzer Regulatory Consulting & Services
Greenlight Clinical
Gwo xi Stem Cell
GX Acquisition
Qihan Biotech
Hanyang University Medical Center
HCW Biologics
Hebei Yanda Ludaopei Hospital
Help Therapeutics
Henan Cancer Hospital
Histocell
Hope Biosciences
Hospital Clinico Universitario de Valladolid
Hospital del Rio Hortega
Hospital for Special Surgery
Hospital Infantil Universitario Nino Jesus
Hospital San Carlos
Hospital Vera Cruz
Huashan Hospital
Hyundai Bioland
iCAR Bio Therapeutics
iCell Gene Therapeutics
ICON plc
Infectious Disease Research Institute (IDRI)
IMAC Regeneration Centers
Immunitybio
Implant Therapeutics
Imugene
IN8bio
Incyte
inno.N
Innovate UK
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Institute of Hematology & Blood Diseases Hospital
Instituto de Salud Carlos III
International Research Institute Servier
Janssen
JCR Pharmaceutical
jCyte
Jiangsu Topcel-KH Pharmaceutical
Jinling Hospital
JW Therapeutics
Kadimastem
Kangstem Biotech
Karolinska Institutet
Kinesiometrics
KSQ Therapeutics
Kuur Therapeutics
Kyocera
Legend Biotech
LG Chem
Lineage Cell Therapeutics
Link Health
Longeveron
Lonza
LUMICKS
Lung Biotechnology PBC
M.D. Anderson Cancer Center
Magellan Stem Cells
Magenta Therapeutics
Masonic Cancer Center
MaxCyte
Mayo Clinic
McGill University Health Centre
Medac
Medeor Therapeutics
Medical University of South Carolina
MEDIPOST
Medpace
Medsenic
Memorial Sloan Kettering Cancer Center
Mendus
Merck Sharp & Dohme
Mercy Gilbert Medical Center
Mesoblast
Ministerio de Ciencia e Innovacion
Ministry of Health & Welfare (MOHW)
Nanfang Hospital of Southern Medical University
Nanjing Bioheng Biotech
Nanjing Enricnk Biotech
NantKwest
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute of Health Research and Development (NIHRD) (Indonesia)
National University Hospital, Singapore
Nature Cell
Neurona Therapeutics
NexImmune
NextCell Pharma
Nippon Shinyaku
Nkarta Therapeutics
Nohla Therapeutics
Northern Therapeutics
Novartis Pharmaceuticals
NuVasive
Ohio State University Comprehensive Cancer Center
OmniaBio
Oncternal Therapeutics
Ono Pharmaceutical
Orca Bio
Orthofix
Osiris Therapeutics
Ossium Health
Overland Pharmaceuticals
Pandorum International
PersonGen BioTherapeutics (Suzhou)
Pfizer
Pharmicell
Phio Pharmaceuticals
Pieris Pharmaceuticals
Pierre Fabre
Pluristem Therapeutics
Poseida Therapeutics
PPD
Precision BioSciences
Precision Biotech
Pregene
ProMab Biotechnologies
Promethera Biosciences
Protech Pharmaservices
PT Prodia StemCell Indonesia (ProSTEM)
Pulthera
Q Therapeutics
Quintiles
R3 Stem Cell
Red de Terapia Celular
Regeneus
ReNeuron
Renji Hospital
Renmin Hospital of Wuhan University
Restem
resTORbio
RHEACELL
Rigenerand
Rigshospitalet
Roche
Royal Brompton and Harefield hospitals
Ruijin Hospital
S.Biomedics
Salvat
Sanofi
Santen Pharmaceutical
Sclnow Biotechnology
SCM Lifescience
Second Affiliated Hospital of Xi'an Jiaotong University
Sentien Biotechnologies
Seoul CRO
Servier
Shanghai Changzheng Hospital
Shanghai East Hospital
Shanghai GeneChem
Shanghai General Hospital
Shanghai iCELL Biotechnology
Shanghai Jiao Tong University School of Medicine
Shanghai Ninth People's Hospital
Shanghai Public Health Clinical Center
Shanghai Sixth People's Hospital
Shenzhen Pregene Biopharma
Shenzhen University General Hospital
Shire
SK Bioland
SMT Bio
Sorrento Therapeutics
Springworks
Staburo
Stanford University
Stemedica Cell Technologies
Steminent Biotherapeutics
Stempeutics Research
Taiga Biotechnologies
Taipei Veterans General Hospital
Taiwan Bio Therapeutics
Talaris Therapeutics
Tang-Du Hospital
TC BioPharm
Teijin Pharma
Tel Aviv Sourasky Medical Center
Tessa Therapeutics
Tevogen Bio
The Affiliated Hospital of Guizhou Medical University
The Affiliated Hospital of Xuzhou Medical University
The Affiliated Union Hospital of Fujian Medical University
The Cleveland Clinic
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Henan University of Science and Technology
The First Affiliated Hospital of Kunming Medical College
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of University of Science and Technology of China
The First Affiliated Hospital of Zhengzhou University
The First People's Hospital of Hefei
The Foundation for Orthopaedics and Regenerative Medicine
The General Hospital of Western Theater Command
The Marcus Foundation
The Methodist Hospital Research Institute
The Netherlands Organisation for Health Research and Development
The Second Affiliated Hospital of Chongqing Medical University
The Second Hospital of Shandong University
The University of Texas Health Science Center
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
TICEBA
TiGenix (Acquired by Takeda)
Timmune Biotech
Tiziana Life Sciences
Translational Biosciences
Trinity College Dublin
Tri-Service General Hospital
Triumvira Immunologics
Tscan Therapeutics
Twist Bioscience
UCI Medical Center
UMC Utrecht
UnicoCell Biomed
Universitatsklinikum Hamburg-Eppendorf
Universiti Kebangsaan Malaysia Medical Centre
Universiti Tunku Abdul Rahman
University Medical Center Groningen
University of California
University of Florida
University of Kansas Medical Center
University of Louisville
University of Miami
University of Minnesota
University of Munich
University of Sydney
University of Valladolid
University of Wisconsin-Madison
Uppsala University
National Cancer Institute
Utooth Biological Technology
VetStem Biopharma
ViaCyte
ViGenCell
Vinmec Research Institute of Stem Cell and Gene Technology
Vinnova
Virginia Contract Research Organization
Viscofan
Vitro Biopharma
Washington University
Wugen
Wuhan Jinyintan Hospital
Xindu (A subsidiary of Xintela)
Xinqiao Hospital of Chongqing
Xintela
Xuzhou Medical University
Zelluna Immunotherapy
Zhejiang University
Zhengzhou University

For more information about this report visit https://www.researchandmarkets.com/r/sa1mvd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets